Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Subscribe To Our Newsletter & Stay Updated